Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM
Publication
, Journal Article
Sampson, JH; Archer, GE; Bigner, DD; Davis, T; Friedman, HS; Keler, T; Mitchell, DA; Reardon, DA; Sawaya, R; Heimberger, AB
Published in: Journal of Clinical Oncology
May 20, 2008
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
2011 / 2011
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Sampson, J. H., Archer, G. E., Bigner, D. D., Davis, T., Friedman, H. S., Keler, T., … Heimberger, A. B. (2008). Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology, 26(15_suppl), 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011
Sampson, J. H., G. E. Archer, D. D. Bigner, T. Davis, H. S. Friedman, T. Keler, D. A. Mitchell, D. A. Reardon, R. Sawaya, and A. B. Heimberger. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 2011–2011. https://doi.org/10.1200/jco.2008.26.15_suppl.2011.
Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology. 2008 May 20;26(15_suppl):2011–2011.
Sampson, J. H., et al. “Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 2011–2011. Crossref, doi:10.1200/jco.2008.26.15_suppl.2011.
Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):2011–2011.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2008
Volume
26
Issue
15_suppl
Start / End Page
2011 / 2011
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences